TL;DR
Get coffee and tea gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Food Safety News publisher says he has filed two citizen petitions asking the FDA to disclose more information about foodborne illness outbreaks and recalls, including company identities and locations. The supplied source describes the petitions and the publisher’s argument for disclosure, but ends before detailing the petitions’ requests or the agency’s response.
A Food Safety News publisher says he has submitted two citizen petitions asking the Food and Drug Administration to disclose more identifying information in food safety communications, including outbreak summaries. He argues the requests follow the agency’s own commitments to “radical transparency,” but the source material available here does not include the petitions’ full wording or an FDA response.
The publisher frames the petitions as a request to put the Department of Health and Human Services’ transparency pledge into practice in food safety. He says they ask for steps the federal government has already taken or said it supports, and writes that, as of October 26, 2026, the Department of Justice had not told the department it lacked authority to take them. That is the publisher’s characterization; the supplied account does not reproduce a Justice Department opinion or the petition texts.
The immediate issue is what FDA includes in summaries of closed outbreak investigations and recall communications. The publisher says the agency has sometimes withheld company names and location details. He cites an FDA mango outbreak summary and a separate summary of a fatal Listeria outbreak, which he says omitted identifying information, including the states where patients lived. Those examples are presented in the opinion piece and are not independently documented in the supplied material.
The article also points to a February citizen petition from Stop Foodborne Illness asking FDA not to treat company names as confidential. According to the publisher, FDA responded that the names were protected by the Trade Secrets Act. He says the legal question has since been answered, but the supplied source text cuts off before giving the explanation, the petitions’ requested remedies, or the basis for that assertion.
What Outbreak Details Could Change
Disclosure of a company name, product brand, or affected location can help consumers identify food they may have bought and make decisions about whether to avoid it. It can also help people connect an illness or exposure to an investigation and understand which businesses or products are under scrutiny. These are the public-interest arguments advanced by the publisher; the source does not quantify the effects of disclosure on illness prevention or recall effectiveness.
The competing concern is that identifying a company during or after an investigation can have legal and commercial consequences, particularly if the information is incomplete or attribution is disputed. The publisher’s argument focuses on making FDA communications more useful, while the agency’s reported reference to the Trade Secrets Act signals a legal issue it says can restrict disclosure. The petitions matter because they ask the agency to address how those interests should be balanced in food safety reporting.
For readers, the practical distinction is between learning that an outbreak occurred and learning enough to identify a relevant product or source. The article argues that summaries without names or locations leave the public with an incomplete picture. Whether the petitions would lead to broader disclosure, and in what circumstances, remains unresolved in the supplied account.
Products Worth Considering
Instant Pot Duo 6-Quart 7-in-1 Electric Pressure Cooker
Instant Pot InstantChill Ice Cream Maker Plus Rolled, No Pre-Freezing, 2‑Pt
Instant Pot Pro 8-Quart 10-in-1 Electric Pressure Cooker, Black
As an affiliate, we earn on qualifying purchases.
FDA’s Transparency Commitments
The publisher traces the phrase “radical transparency” to HHS Secretary Robert F. Kennedy Jr. and the department’s public messaging. At a January 29, 2025, confirmation hearing, Kennedy promised transparency and said, “We should tell Americans when we don’t know.” In a February 18 address to HHS staff, he said transparency was necessary for informed consent.
HHS and FDA later connected the idea to food. On March 10, 2025, HHS directed FDA to explore ending the self-affirmed GRAS pathway; the accompanying release said the agencies wanted Americans to know what was in their food. In July, FDA sent food industry leaders a letter about recall communications that said transparency in food safety and nutrition actions was key to reducing foodborne illness and chronic disease.
In September 2025, FDA’s food program began publishing Executive Incident Summary abstracts for closed outbreak investigations. The publisher credits the summaries as a step forward, while arguing that the omission of company and location details limits their value. FDA leadership has since changed: the source says Commissioner Marty Makary resigned in May 2026, leaving Kyle Diamantas as acting commissioner, and that President Donald Trump nominated Heidi Overton in August.
“The company names are protected by the Trade Secrets Act.”
— FDA, in its reported response to a Stop Foodborne Illness petition, according to the publisher
Petition Requests and FDA Response
The supplied source ends partway through its account of an October chicken-wrap outbreak. It does not provide the complete text of either citizen petition, specify every disclosure change sought, or include a formal FDA acknowledgment or response. It also does not show the legal analysis behind the publisher’s statement that the Justice Department had not told HHS it lacked authority to act.
The publisher describes particular outbreak summaries as lacking names or location details, but the supplied material does not include the underlying FDA records or responses from affected companies. It is also unclear whether the petitions seek disclosure in all investigations or only under specified conditions, and whether FDA would change its approach while an outbreak is active, after it closes, or both.
FDA Review and Further Detail
The next concrete development would be FDA’s handling of the two petitions: whether the agency accepts them for review, requests additional information, or issues a substantive response. The supplied source gives no review schedule or decision date, so the timing is unknown.
Readers will also need the complete petition texts and any agency explanation of how it interprets the Trade Secrets Act in this setting. Until those records or responses are available, the central issue remains whether FDA will disclose more company and location information in outbreak summaries and recall communications, and under what conditions.
Key Questions
What is the publisher asking the FDA to do?
The publisher says two citizen petitions ask FDA to expand disclosure in food safety communications. The supplied source excerpt does not include the petitions’ complete wording, so their precise requested rules are not confirmed here.
Why does the publisher want more outbreak details disclosed?
He argues that company names, brands, and locations can help consumers understand whether an outbreak may involve food they encountered. That is the publisher’s case for disclosure; the supplied material does not provide a measured estimate of its effect.
What reason did FDA reportedly give for withholding company names?
According to the publisher, FDA told Stop Foodborne Illness that company names were protected by the Trade Secrets Act. The full agency response and its legal reasoning are not included in the source excerpt.
Has the FDA agreed to change its disclosure policy?
The supplied material does not report an FDA decision on these two petitions or say that the agency has changed its policy. Its response and the petitions’ review status are unclear.
Source: foodsafetynews.com
